JP2018510191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510191A5 JP2018510191A5 JP2017551589A JP2017551589A JP2018510191A5 JP 2018510191 A5 JP2018510191 A5 JP 2018510191A5 JP 2017551589 A JP2017551589 A JP 2017551589A JP 2017551589 A JP2017551589 A JP 2017551589A JP 2018510191 A5 JP2018510191 A5 JP 2018510191A5
- Authority
- JP
- Japan
- Prior art keywords
- tautomers
- solvates
- stereoisomers
- salts
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- -1 3-difluoromethoxy-5-fluoropyridin-4-yl Chemical group 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 150000003058 platinum compounds Chemical class 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 241000507627 Salana Species 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15000968 | 2015-04-02 | ||
| EP15000968.6 | 2015-04-02 | ||
| PCT/EP2016/000542 WO2016155884A1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020185129A Division JP7111790B2 (ja) | 2015-04-02 | 2020-11-05 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510191A JP2018510191A (ja) | 2018-04-12 |
| JP2018510191A5 true JP2018510191A5 (OSRAM) | 2019-05-16 |
| JP6791873B2 JP6791873B2 (ja) | 2020-11-25 |
Family
ID=52814780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551589A Active JP6791873B2 (ja) | 2015-04-02 | 2016-03-31 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
| JP2020185129A Active JP7111790B2 (ja) | 2015-04-02 | 2020-11-05 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020185129A Active JP7111790B2 (ja) | 2015-04-02 | 2020-11-05 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10457677B2 (OSRAM) |
| EP (3) | EP3277681B1 (OSRAM) |
| JP (2) | JP6791873B2 (OSRAM) |
| KR (2) | KR20240044525A (OSRAM) |
| CN (3) | CN111689963A (OSRAM) |
| AU (4) | AU2016239270B2 (OSRAM) |
| BR (1) | BR122019005502B1 (OSRAM) |
| CA (1) | CA2981365A1 (OSRAM) |
| DK (2) | DK3277681T3 (OSRAM) |
| ES (3) | ES2741853T3 (OSRAM) |
| HR (2) | HRP20191396T1 (OSRAM) |
| HU (2) | HUE054745T2 (OSRAM) |
| IL (3) | IL254714B (OSRAM) |
| LT (2) | LT3277681T (OSRAM) |
| MX (2) | MX390537B (OSRAM) |
| PL (2) | PL3560924T3 (OSRAM) |
| PT (2) | PT3277681T (OSRAM) |
| RS (2) | RS59139B1 (OSRAM) |
| RU (1) | RU2743343C2 (OSRAM) |
| SG (2) | SG10202002181UA (OSRAM) |
| SI (2) | SI3277681T1 (OSRAM) |
| TR (1) | TR201911244T4 (OSRAM) |
| WO (1) | WO2016155884A1 (OSRAM) |
| ZA (1) | ZA201707423B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054745T2 (hu) * | 2015-04-02 | 2021-09-28 | Merck Patent Gmbh | Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| WO2018153365A1 (zh) * | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| JP2021510701A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| CA3093499A1 (en) | 2018-03-14 | 2019-09-19 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| BR112020018006A2 (pt) | 2018-04-12 | 2021-01-12 | Bayer Aktiengesellschaft | Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1h-1,2,4-triazol-5-il]etil}benzamida e os derivados correspondentes de piridina-carboxamida como pesticidas |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
| CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
| CN112771045B (zh) * | 2018-09-30 | 2022-04-19 | 南京明德新药研发有限公司 | 喹啉并吡咯烷-2-酮类衍生物及其应用 |
| RS65518B1 (sr) | 2019-03-27 | 2024-06-28 | Merck Patent Gmbh | Jedinjenja imidazolonilhinolina i njihova terapijska upotreba |
| CN119684291A (zh) * | 2019-07-30 | 2025-03-25 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| IL292613A (en) * | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer |
| US11685734B2 (en) | 2019-12-04 | 2023-06-27 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
| CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| EP4168010A1 (en) * | 2020-06-18 | 2023-04-26 | Merck Patent GmbH | Compounds for the treatment of viral infections |
| US20230256110A1 (en) | 2020-06-24 | 2023-08-17 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
| MX2023002792A (es) | 2020-09-18 | 2023-03-16 | Merck Patent Gmbh | Preparacion farmaceutica. |
| WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN115232122B (zh) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 炔类化合物及其制备和应用 |
| CN115716829B (zh) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
| US12384808B2 (en) | 2022-11-23 | 2025-08-12 | Forward Therapeutics, Inc. | Modulators of TNF-α activity |
| WO2025157979A1 (en) | 2024-01-26 | 2025-07-31 | Merck Patent Gmbh | Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| WO2006100226A1 (en) * | 2005-03-21 | 2006-09-28 | Ferrer Internacional, S. A. | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린 |
| CA2717948C (en) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| RS54560B1 (sr) | 2008-06-10 | 2016-06-30 | Abbvie Inc. | Triciklična jedinjenja |
| RU2519200C2 (ru) | 2008-10-01 | 2014-06-10 | Новартис Аг | Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений |
| AU2010255727B2 (en) | 2009-06-04 | 2013-02-28 | Novartis Ag | 1H-imidazo[4,5-c]quinolinone derivatives |
| JP2012528829A (ja) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物 |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN102803227B (zh) * | 2010-03-16 | 2016-01-20 | 默克专利有限公司 | 吗啉基喹唑啉 |
| US8791113B2 (en) * | 2010-06-28 | 2014-07-29 | Merck Patent Gmbh | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| US20130245061A1 (en) | 2010-12-03 | 2013-09-19 | Novartis Ag | Pharmaceutical compositions |
| CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| WO2013184621A1 (en) | 2012-06-06 | 2013-12-12 | Novartis Ag | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
| NO2714752T3 (OSRAM) | 2014-05-08 | 2018-04-21 | ||
| HUE054745T2 (hu) | 2015-04-02 | 2021-09-28 | Merck Patent Gmbh | Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként |
-
2016
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Pending
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de not_active Ceased
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 MX MX2020011558A patent/MX390537B/es unknown
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2016-03-31 MX MX2017012613A patent/MX376947B/es active IP Right Grant
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active Active
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
-
2025
- 2025-01-20 AU AU2025200385A patent/AU2025200385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510191A5 (OSRAM) | ||
| CN111214471B (zh) | 药物组合物及其用途 | |
| JP2016523974A5 (OSRAM) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2015096544A5 (OSRAM) | ||
| JPWO2019191470A5 (OSRAM) | ||
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| JP2019501204A5 (OSRAM) | ||
| JP2016528162A5 (OSRAM) | ||
| JP2009523801A (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| JP2013544846A5 (OSRAM) | ||
| JP2010528995A5 (OSRAM) | ||
| JP2016501221A5 (OSRAM) | ||
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2015515961A5 (OSRAM) | ||
| JP2020097596A5 (OSRAM) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2011510028A5 (OSRAM) | ||
| JP2018062523A5 (OSRAM) | ||
| ES2945865T3 (es) | Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina | |
| JP2017530154A5 (OSRAM) | ||
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| JP2014530181A5 (OSRAM) | ||
| ES2385850T3 (es) | Potenciador de radioterapia | |
| HRP20171783T1 (hr) | Derivati imidazopirazinona |